This Informed Consent document applies to your use of telehealth services and GLP-1 receptor agonist medications provided through the TrimDoctor platform, operated by Peak Asset Performance LLC ("TrimDoctor," "we," "us," or "our"). Please read this document carefully before proceeding with treatment.
I. Consent to Telehealth Services
By using TrimDoctor, you understand and agree to the following regarding telehealth-delivered healthcare:
- Your healthcare will be delivered via telehealth (remotely), not through an in-person visit
- Telehealth has inherent limitations, including the inability of your provider to perform a physical examination
- Your provider will rely on the information you provide, including your medical history, symptoms, and current health status
- Your provider may recommend an in-person visit with a local healthcare provider if they determine it is medically necessary
- You have the right to withdraw your consent to telehealth services at any time
- Technical difficulties (internet connectivity, device issues) may occur and could interrupt or delay your care
II. Consent to GLP-1 Receptor Agonist Medication
A. Expected Benefits
GLP-1 receptor agonist medications (semaglutide and tirzepatide) have been shown to:
- Reduce appetite and food cravings
- Promote significant weight loss
- Achieve an average of 15–20% body weight reduction in clinical studies
Individual results will vary. The amount and rate of weight loss depend on multiple factors including adherence to medication, dosage, diet, exercise, and individual metabolism.
B. Common Side Effects
The following side effects are commonly reported and typically subside within the first few weeks of treatment:
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
- Constipation
- Abdominal pain
- Headache
- Fatigue
- Injection site reactions (for injectable formulations)
C. Serious Risks
BLACK BOX WARNING: In animal studies, GLP-1 receptor agonists (including semaglutide and tirzepatide) have been shown to cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including MTC, in humans. DO NOT USE this medication if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Additional serious risks include, but are not limited to:
- Pancreatitis — Inflammation of the pancreas, which can be severe
- Gallbladder problems — Including gallstones and cholecystitis
- Kidney problems — Including acute kidney injury, especially with dehydration
- Serious allergic reactions — Including anaphylaxis and angioedema
- Vision changes — Diabetic retinopathy complications (in patients with type 2 diabetes)
- Increased heart rate
- Depression or suicidal thoughts — Rare but reported; seek immediate help if experiencing these symptoms
- Muscle loss — Potential loss of lean muscle mass during rapid weight loss
- Nutritional deficiencies — Due to reduced food intake
III. Consent to Compounded Medication
The compounded medications provided through TrimDoctor are NOT FDA-approved finished products. Compounded medications have not undergone the same testing and approval process as commercially manufactured FDA-approved drugs. Compounded formulations may differ from FDA-approved versions in formulation, concentration, and/or inactive ingredients.
By consenting to treatment, you acknowledge that you understand these differences and that the decision to prescribe a compounded medication is made by your independently licensed healthcare provider based on their clinical judgment.
IV. Patient Responsibilities
As a patient, you agree to the following responsibilities:
- Provide truthful and complete information about your medical history, current health conditions, and medications
- Notify your care team immediately if you experience any adverse effects or unusual symptoms
- Follow all medication instructions provided by your physician, including dosage and administration
- Report any changes in your health status, including new diagnoses or medications
- Do not share, sell, or transfer your medication to any other person
- Store injectable medications properly at 36–46°F (2–8°C) as directed
- Attend scheduled follow-up consultations and monthly check-ins
- Seek emergency medical care immediately for severe adverse effects
V. Consent to Communications
By using the Platform, you consent to receive communications from TrimDoctor through the following channels:
- Email
- SMS text messages
- Patient portal notifications
- Push notifications (if enabled)
You may opt out of marketing communications at any time. Transactional communications (appointment reminders, shipping updates, safety alerts) are required while you maintain an active subscription and cannot be opted out of.
VI. Acknowledgment
By proceeding with TrimDoctor services, you acknowledge and confirm that:
- You have read and understand this Informed Consent document in its entirety
- You have had the opportunity to ask questions about the treatment, risks, and alternatives
- You voluntarily consent to telehealth services and GLP-1 medication therapy
- You may withdraw your consent at any time by canceling your subscription through the patient portal or contacting support